<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4111">
  <stage>Registered</stage>
  <submitdate>27/08/2013</submitdate>
  <approvaldate>27/08/2013</approvaldate>
  <nctid>NCT01931670</nctid>
  <trial_identification>
    <studytitle>A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-004295-11</secondaryid>
    <secondaryid>M12-671</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Endometriosis</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Menstruation and menopause</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Elagolix
Other interventions - placebo

Experimental: Elagolix Dose 1 - 6 Month Treatment Period

Experimental: Elagolix Dose 2 - 6 Month Treatment Period

Placebo Comparator: Placebo - 6 Month Treatment with matching Placebo


Treatment: drugs: Elagolix
Elagolix Dose 1 for 6 month Treatment Period, Elagolix Dose 2 for the 6 month Treatment Period

Other interventions: placebo
Placebo for 6 Month Treatment Period

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of responders based on daily assessment of Dysmenorrhea (DYS) - This was assessed by the e-Diary.</outcome>
      <timepoint>At Month 3</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of responders based on daily assessment of Non-menstrual pelvic pain (NMPP) - This was assessed by the e-Diary.</outcome>
      <timepoint>At Month 3</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to each month in Numeric rating scale (NRS) scores - This was assessed by the e-Diary.</outcome>
      <timepoint>From Baseline (Prior to administering study drug) to Month 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to each month in Dysmenorrhea (DYS) - This was assessed by the e-Diary.</outcome>
      <timepoint>From Baseline (Prior to administering study drug) to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to each month in Non-menstrual pelvic pain (NMPP) - This was assessed by e-Diary.</outcome>
      <timepoint>From Baseline (Prior to administering study drug) to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in analgesic use across both classes of rescue analgesics based on pill counts - This was assessed using e-Dairy.</outcome>
      <timepoint>Baseline (Prior to administering study drug), Month 3 and Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to each month in dyspareunia - This was assessed using the e-Diary.</outcome>
      <timepoint>From Baseline (Prior to administering study drug) to Month 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in use of narcotic class of medication based on pill counts - This was assessed using by the e-Diary.</outcome>
      <timepoint>From Baseline (Prior to administering study drug) to Month 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of responders for each month, except month 3, in DYS - This is measured by the daily assessment of Endometriosis pain.</outcome>
      <timepoint>Up to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of responders at each month for dyspareunia - This was assessed by the e-Diary.</outcome>
      <timepoint>Up to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to each month, except Month 6, in the mean pain score for DYS - This was assessed by the e-Diary.</outcome>
      <timepoint>From Baseline (Prior to administering study drug) to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to each month, except Month 3, in the mean pain score of dyspareunia - This was assessed by the e-Diary.</outcome>
      <timepoint>From Baseline (Prior to administering study drug) to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to each month, except Months 3 and 6, in analgesic use across both classes of rescue analgesics to treat endometriosis-related pain - This was assessed by the e-Diary.</outcome>
      <timepoint>From Baseline (Prior to administering study drug) to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient Global Impression of Change (PGIC) questionnaire - This is assessed using PGIC questionnaire.</outcome>
      <timepoint>Up to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to each month, except month 3, in NRS scores - This was assessed by the e-Diary.</outcome>
      <timepoint>From Baseline (Prior to administering study drug) to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to each scheduled assessment in the pain domain of Endometriosis Health Profile-30 (EHP-30) questionnaire scores - This is assessed using EHP-30 questionnaire scores.</outcome>
      <timepoint>From Baseline (Prior to administering study drug) to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to each scheduled assessment in the sexual relationship domain of EHP-30 questionnaire scores - This is assessed using EHP-30 questionnaire scores.</outcome>
      <timepoint>From Baseline (Prior to administering study drug) to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to each scheduled assessment in Health Related Productivity Questionnaire (HRPQ) scores - This is assessed using HRPQ scores.</outcome>
      <timepoint>From Baseline (Prior to administering study drug) to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of endometriosis-related non-study health visits - This is assessed using Health Resource Utilization Questionnaire (HRUQ).</outcome>
      <timepoint>Up to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of days in the hospital - This is assessed using Health Resource Utilization Questionnaire (HRUQ).</outcome>
      <timepoint>Up to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessing type of procedures performed - This is assessed using Health Resource Utilization Questionnaire (HRUQ).</outcome>
      <timepoint>Up to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of responders for each month, except month 3, in NMPP - This is measured by the daily assessment of Endometriosis pain.</outcome>
      <timepoint>Up to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to each month, except Month 6, in the mean pain score for NMPP - This was assessed by the e-Diary.</outcome>
      <timepoint>From Baseline (Prior to administering study drug) to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline to each month in the mean pain score for DYS - via eDiary</outcome>
      <timepoint>From baseline (prior to study drug administration) to Month 6 of Treatment Period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline to each month in the mean pain score for NMPP - via eDiary</outcome>
      <timepoint>From baseline (prior to study drug administration) to Month 6 of Treatment Period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Premenopausal female, between 18 and 49 years of age, inclusive, at the time of
             signing consent.

          2. Clinical diagnosis of endometriosis (laparoscopy or laparotomy) performed within 10
             years of entry into the Washout Period.

          3. Agrees to use required birth control methods during the entire length of participation
             in the study.

          4. Subject has a Composite Pelvic Signs and Symptoms Score total score of 6 at Screening
             with a score of at least 2 for dysmenorrhea AND at least 2 for non-menstrual pelvic
             pain.

          5. Subjects must have at least two regular menstrual cycles with an interval of 24-38
             days within the Screening Period, prior to Day 1.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>49</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Subject is pregnant or breast feeding or is planning a pregnancy within the next 24
             months or is less than 6 months postpartum, post-abortion, or post-pregnancy at the
             time of entry into the Screening Period.

          2. Subject has a history of previous non-response to gonadotropin-releasing hormone
             (GnRH) agonists, GnRH antagonists, Depot medroxyprogesterone acetate, or aromatase
             inhibitors as assessed by subject report of no improvement in dysmenorrhea or
             non-menstrual pelvic pain.

          3. Subject has chronic pelvic pain that is not caused by endometriosis that requires
             chronic analgesic or other chronic therapy, or that would interfere with the
             assessment of endometriosis related pain.

          4. Clinically significant gynecologic condition identified on Screening transvaginal
             ultrasound or endometrial biopsy.

          5. Subject has a history of osteoporosis or other metabolic bone disease.

          6. Subject has a current history of undiagnosed abnormal uterine bleeding.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>818</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Robinson Institute, The Univ Adelaide /ID# 115055 - Adelaide</hospital>
    <hospital>Wesley Medical Centre /ID# 101076 - Auchenflower</hospital>
    <hospital>Keogh Institute for Medical Research /ID# 95856 - Nedlands</hospital>
    <hospital>Womens Health Research Institute of Australia /ID# 94233 - Sydney</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>QLD 4066 - Auchenflower</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>2000 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Rosario, Sante Fe CP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Rosario, Sante Fe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Villach</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Bela Vista, Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Belo Horizonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Campinas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Ribeirao Preto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio de Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ceske Budejovice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Jihlava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Plzen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague 10</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague 8</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Pribram</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Zlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Bekescsaba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Eger</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kaposvar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Nyiregyhaza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Siofok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Florence</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genoa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Monserrato Cagliari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Naples</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Sassari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Siena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Turin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Beckenham, Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Birkenhead, Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Katowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw 44</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Lyttelton, Centurion</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Parow, Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pinelands, Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Port Elizabeth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cordoba-(Espana)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>El Palmar, Murcia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Seville</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dorchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Lancashire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Norwich, Norfolk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A randomized study evaluating the safety and efficacy of elagolix in the management of
      moderate to severe endometriosis-associated pain in adult premenopausal female subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01931670</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>AbbVie Inc</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>